{
    "title": "RSS Feed Title",
    "link": "https://example.com",
    "description": "RSS Feed Description",
    "lastBuildDate": "2026-01-16T00:54:14.564498",
    "items": [
        {
            "title": "Can domestic formulations shield Indian pharma from US pricing pressure in Q3?",
            "link": "https://economictimes.indiatimes.com/markets/stocks/earnings/can-domestic-formulations-shield-indian-pharma-from-us-pricing-pressure-in-q3/articleshow/126555072.cms",
            "description": "Indian drugmakers anticipate a mixed third quarter. Domestic sales and new specialty drugs will drive growth. US generics will see new product boosts. Contract services and APIs are set for moderate gains. Sun Pharma and Lupin are poised for leadership. Cipla and Dr Reddy's face softer US sales. Divi's Laboratories expects strong custom synthesis growth.",
            "pubDate": "2026-01-16T00:54:14.011661"
        }
    ]
}